WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference.
Presentation Details:
Date: December 5, 2024
Time: 10:30-10:55 am Eastern Time
Location: Lotte New York Palace, NY, NY
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF)…
Invensify and Go2 Delivery Partner to Revolutionize Sustainable Pharmacy Courier Services VIRGINIA BEACH, Va., May…
Integration brings Torchlight's leading caregiving solution to WebMD's wellbeing platform, enhancing support for working families…
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 13,…
ST. PAUL, Minn., May 13, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems…
DALLAS, May 13, 2025 /PRNewswire/ -- Scout, a premier provider of clinical trial services, has…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
